NCT02724358View on ClinicalTrials.gov

Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

NACompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2015

Conditions
Hepatocellular CarcinomaTACENotch1Rg3
Interventions
PROCEDURE

TACE

iodized oil (5ml) + Pirarubicin (20mg)

DRUG

Rg3

20mg, BID, maintained though Month 12.

OTHER

TACE + Rg3

PROCEDURE

protective therapy

standard liver protective therapy

Trial Locations (1)

200438

Eastern hepatobilliary surgery hospital, Shanghai

All Listed Sponsors
lead

Eastern Hepatobiliary Surgery Hospital

OTHER

NCT02724358 - Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1 | Biotech Hunter | Biotech Hunter